Author

A. Stefanachi

h-index 24 View on Semantic Scholar

We have 3 of 72 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Discovery of a Peripherally Directed CB1 Receptor Antagonist That Restores Insulin Signaling in Adipocytes

Piperazine-1-ium derivative 24a stands out as the first permanently charged CB1R antagonist, exhibiting nanomolar affinity and high CB1R/CB2R selectivity with a favorable physicochemical profile consistent with peripheral restriction and limited blood-brain barrier penetration.

J. Azuaje, Rubén Prieto-Díaz, Claudia Gioé-Gallo et al. · ACS Omega · 0 citations

Oct 2026

Design and Development of New Dual Target Agents, Cannabinoid Subtype 2 Receptor (CB2R) Agonists, and Fatty Acid Amide Hydrolase (FAAH) Inhibitors against Neurodegeneration

As dual modulators of Cannabinoid subtype 2 receptor (CB2R) and fatty acid amide hydrolase (FAAH)an arising therapeutic strategy against diseases based on neuroinflammationwe developed a new series of N-adamantyl-benzamides bearing an anthranilic or salicylic scaffold. Derivatives 18, 22, and 25 emerged as an inter...

Giovanni Graziano, Francesco Mastropasqua, A. Fanizzi et al. · Journal of Medicinal Chemist... · 0 citations

Review Open access Aug 2026

PROTAC-Based Strategies in Neurodegenerative Diseases: Challenges and Perspectives

This review summarizes recent advances in chemical protein degradation strategies for neurodegenerative disorders and highlights potential future perspectives of multifunctional PROTACs for therapeutic development.

Pasquale Degennaro, Imane Ghafir El Idrissi, Rosa Purgatorio et al. · Pharmaceuticals · 0 citations